NCT07105228View on ClinicalTrials.gov

Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study

CompletedOBSERVATIONAL
Enrollment

290,000

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

August 30, 2025

Study Completion Date

September 15, 2025

Conditions
Retinal Vasculitis
Interventions
DRUG

aflibercept 2mg

No study-specific interventions administered in this observational study

Trial Locations (1)

10591

Regeneron Research Site, Tarrytown

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY